MedPath

Betaine

Generic Name
Betaine
Brand Names
Amversio, Cystadane, EnBrace HR, EnLyte
Drug Type
Small Molecule
Chemical Formula
C5H11NO2
CAS Number
107-43-7
Unique Ingredient Identifier
3SCV180C9W
Background

Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine. It is a naturally occurring choline derivative commonly ingested through diet, with a role in regulating cellular hydration and maintaining cell function. Homocystinuria is an inherited disorder that leads to the accumulation of homocysteine in plasma and urine. Currently, no treatments are available to correct the genetic causes of homocystinuria. However, in order to normalize homocysteine levels, patients can be treated with vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and specific diets. Betaine reduces plasma homocysteine levels in patients with homocystinuria. Although it is present in many food products, the levels found there are insufficient to treat this condition. The FDA and EMA have approved the product Cystadane (betaine anhydrous, oral solution) for the treatment of homocystinuria, and the EMA has approved the use of Amversio (betaine anhydrous, oral powder).

Indication

Betaine is indicated for the treatment of homocystinuria in pediatric and adult patients to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl).

Associated Conditions
Homocystinuria, Homocystinuria Due to Cystathionine Beta-Synthase Deficiency, Homocystinuria due to MTHFR deficiency, Homocystinuria due to cobalamin cofactor metabolism (cbl) defect

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

Phase 2
Completed
Conditions
Hepatitis C
First Posted Date
2006-04-03
Last Posted Date
2010-10-28
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
30
Registration Number
NCT00310336
Locations
🇨🇭

University Hospital Basel, Basel, BS, Switzerland

Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria

Phase 2
Completed
Conditions
Hyperoxaluria
Interventions
Drug: Placebo
First Posted Date
2006-01-27
Last Posted Date
2013-12-16
Lead Sponsor
Mayo Clinic
Target Recruit Count
15
Registration Number
NCT00283387
Locations
🇺🇸

Mayo Clinic Hyperoxaluria Center, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath